Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00274235
Status:
COMPLETED
Last Update Posted:
2008-10-31
First Post:
2006-01-09
Brief Title:
Intermittent Preventive Treatment During Pregnancy in Benin
Sponsor:
Institut de Recherche pour le Developpement
Organization:
Institut de Recherche pour le Developpement
Study Overview
Official Title:
Intermittent Preventive Treatment During Pregnancy in Benin a Randomized Open and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Malaria in pregnancy is one of the most important preventable causes of low birthweight worlwide and a major cause of severe maternal anaemia contributing to maternal mortality Intermittent Preventive Treatment IPT with sulfadoxine-pyrimethamine SP is the currently adopted government recommendation for malaria control during pregnancy in Benin but the emergence and the spread of resistance to SP justifies the evaluation of alternative anti-malarial drugs Mefloquine MQ which has been proven effective and reasonably safe in this indication may be an interesting alternative to SP The aim of this trial is to compare the efficacy and safety of sulfadoxine-pyrimethamine and mefloquine for IPT It is an equivalent study designed to test the hypothesis that MQ is as efficacious as SP to prevent malaria in pregnancy and that it could replace SP when resistance of Plasmodium falciparum becomes too elevated Primary endpoint will be the proportion of infants with low birthweight Secondary endpoints will be the proportion of mothers with placental plasmodial infection and the proportion of mothers with anaemia at delivery
Detailed Description:
The trial will be conducted in two maternity clinics in Ouidah 40km from Cotonou A total of 1600 women will be selected and randomised to receive either SP 1500 mg sulfadoxine with 75 mg pyrimethamine or MQ 15 mgkg twice during pregnancy at ante-natal clinic ANC visits The first dose will be given between 16 and 28 weeks of gestation the second between 30 and 36 weeks and at least one month after the first dose Women will be visited at home within one week after the initial and subsequent ANC visits to check for adverse reactions due to the study drugs Peripheral blood samples will be collected on each ANC visit to assess for haemoglobin level and parasitemia Peripheral placental and cord blood samples will be collected at delivery for haematological determinations and parasitological examination Birthweight will be recorded and the gestational age assessed by the Ballard method The mother and her child will be assessed for general health status six weeks after birth
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None